GSK India Managing Director Hasit Joshipura On Business Dynamics In India, Tiered Pricing And Approaches To Rural Markets: An Interview With PharmAsia News (Part 2 Of 2)
This article was originally published in PharmAsia News
Executive Summary
Hasit Joshipura, GlaxoSmithKline's India Managing Director is unfazed by the recent mega-deal that Abbott struck with Piramal Healthcare - catapulting the U.S. giant to the number one slot in India with a market share of nearly 7 percent.
You may also be interested in...
Glaxo Seeks Indian Consumer Growth, Expanded Capacity
GSK hopes to grow in all three of its business areas – consumer healthcare, pharmaceuticals and vaccines – in India with product introductions and a strategy to expand further into rural markets. CEO Andrew Witty previously headed Glaxo’s Asia Pacific operations and says he is a “huge bull on India.”
Glaxo Seeks Indian Consumer Growth, Expanded Capacity
GSK hopes to grow in all three of its business areas – consumer healthcare, pharmaceuticals and vaccines – in India with product introductions and a strategy to expand further into rural markets. CEO Andrew Witty previously headed Glaxo’s Asia Pacific operations and says he is a “huge bull on India.”
GSK Shoots For Next Growth Phase In India With Bigger Push Into Vaccines, Pharma And Consumer Health
For the first time, the global board of directors of the British pharma and consumer healthcare giant met in India, and a series of moves to power further growth could be on the way.